Asthma is characteristic with chronic airway inflammation and remodeling. Azithromycin (AZM), the 15-member macrolide, is known to present an anti-inflammatory effect and is increasingly being used in the treatment of chronic inflammatory pulmonary diseases. We hypothesize that low-dose azithromycin can inhibit allergen-induced airway remodeling except allergic airway inflammation in rat model. Male SD rats underwent intraperitoneal ovalbumin sensitization on days 1 and 6 followed by an intranasal challenge on day 7-13. On day 14, airway inflammation and remodeling were assessed by quantifying leukocytes in the airway, expression of multiple inflammatory mediators in BALF, histological examination in lung and TGF-pl mRNA and protein levels by qRT-PCR, immunohistochemistry and Western blotting. Treatment with low-dose azithromycin at the dose of 25 mg/kg significantly reduced ovalbumin-dependent airway inflammation, including accumulation of neutrophils, lymphocytes and eosinophils, secretion of IL-2, IL-4, IL-13 and TNF-a. Moreover, airway remodeling was significantly abrogated by azithromycin in this model. The mucus cell hyperplasia, thickening of the peribronchial smooth muscle layer, secretion of ET-l,IL-2, IL-4, IL-13 and TNF-a, and increasing mRNA and protein expressions ofTGF-pl in lung tissue were all significantly decreased in azithromycin-treated rats. These findings demonstrate the protective effect of low-dose azithromycin on allergic airway remodeling in rat and suggest low-dose azithromycin may have beneficial effects in treating allergic airway inflammation.
asthma well-controlled by ICS therapy. Recently, there is increasing evidence that macrolide antibiotics, such as Azithromycin (AZM), have a large number of anti-inflammatory and immune-modifying properties in addition to being antimicrobials (4) (5) (6) (7) (8) (9) . Long-term administration of azithromycine at the dose of 250 mg orally has been observed to reduce the severity of bronchial hyperresponsiveness in patients with mild asthma (10) . To the best of our knowledge, there is no available study that evaluates the effects of low-dose azithromycin treatment on airway remodeling in an experimental rat model, although the anti-inflammatory effect of azithromycin has been confirmed.
To determine whether low-dose azithromycin attenuated ovalbumin-induced allergic airway remodeling in rat, we synthetically evaluated the ability of low-dose azithromycin to alleviate ovalbumin-dependent airway remodeling and inflammation in rat model.
MATERIALS AND METHODS

Experimental animals
Male Sprague-Dawley rats (n=40) weighing 190-210 g were purchased from Da-Shuo Biological Technology Co., Ltd. (Chengdu, China). Animals were allowed free access to standard diet and sterile water in a restricted access temperature-controlled (20± 1"C) and humiditycontrolled (60±1O%) room under 12-h light/12-h dark conditions. All the experimental procedures were performed in accordance with the guidelines of the Experimental Research Institute of Sichuan University in agreement with the guidelines of the Canadian Council on Animal Care. All rats were randomly divided into four groups: (l) control (saline challenge); (2) ovalbumin (OVA) challenge; (3) OVA challenge plus 0.5 mg/kg dexamethasone (DXM, positive control), and (4) OVA challenge plus 25 mg/kg azithromycin (corresponding to human clinical equivalent dosage).
Sensitization and antigen challenge protocol
Rats were sensitized by subcutaneous injection of 1 ml of saline containing I mg of OVA (Sigma-Aldrich, USA) and 200 rng aluminum hydroxide (Aldrich, USA) in I ml of saline on day I and 6. Rats were challenged through the airway with I% OVA for 30 min using an ultrasonic nebulizer (NE-U I2; Omron Co., Tokyo, Japan) once daily from day 7 to 13 after initial sensitization. The control animals were exposed to saline in a similar manner. On day 8-13, allergen-sensitized rats were treated by oral gavage with 0.2 ml of saline containing dexamethasone (0.5 mg/kg) or azithromycin (25 mg/kg) I h prior to ovalbumin administration. The control rats were treated in the same way with normal saline. A schematic diagram of the treatment schedule is shown in Fig. 1 .
Collection of blood and Bronchoalveolar Lavage Fluid (BALF)
Twenty-four hours after the final OVA challenge, rats were anesthetized intraperitoneally with 10% chloral hydrate dose of 300 mg/kg and serum, bronchoalveolar lavage fluid (BALF) and lung tissues were obtained.
Serum IgE
Blood was collected and centrifuged at 4°C (3000 rpm) for 5 min, and the serum was stored at -80°C for measurement of total IgE levels by ELISA.
Infiammatory cell counts in bronchoalveolar lavage fluid (BALF)
Bronchoalveolar lavage (BAL) fluids were performed by an intratracheal injection of2 ml ofwann saline (37°C) for 2 times to recover a total volume of 2.4-3.2 ml. The resultant BALF was centrifuged 5 min (3000 rpm) at 4°C. The cell pellets were resuspended in a I ml of PBS and then applied to a slide by cytospinning for differential cell counts by staining with a modified Giemsa method. At least 200 cells were counted per slide.
Measurement ofEndothelin-i fET-i] and cytokine levels in BALF
The ET-1, IL-2, IL-4, IL-5, IL-13 and TNF-a concentration in BALF were measured using commercially available ELISA kits (R&D, USA), according to the manufacturer's protocol.
Lung tissue histopathology
After BALF was obtained, left lung tissue was fixed in 10% (v/v) neutral-buffered formalin for 24 h at 4°C. Tissues were embedded in paraffin, sectioned at 4 urn thickenss, and examined for airway inflammation, goblet cell metaplasia, and subepithelial fibrosis with hematoxylin and eosin, Periodic acid-Schiff, and Masson trichrome stains, respectively, as described previously. The airway wall thickness (Wat) and the bronchial smooth muscle thickness (Wam) were quantified using Image-Pro® Plus 6.0 software. The inflammation score was calculated by 2 independent observers who were blinded to the experiment. Goblet cell hyperplasia was assessed by histologic analysis of periodic acid-Schiff (PAS)stained lung sections and the percentage of PAS-positive cells was counted in four airways from one section. Masson trichrome stain was used here to detect collagen deposition in the lung tissues by classification on a 0-4 scale. The score was also calculated by 2 independent observers who were blinded to the experiment.
Immunohistochemistry
Sections were cleared of paraffin, and endogenous peroxidases were blocked by incubation with 3% HP2 and washed. Sections of the tissues were then incubated with rabbit serum for 10 min at ambient temperature. Subsequently, the sections were incubated overnight with a goat polyclonal anti-TGf'-jll (sc-146, Santa Cruz, USA) (I: 100) at 4°C, followed by the addition of biotinylated rabbit anti-goat immunoglobulin G secondary antibody. To verify the binding specificity for TGF-~I, some sections were also incubated with a primary antibody only (no secondary) or with a secondary antibody only (no primary). In these situations, no positive staining was found in the sections, indicating that the immunoreactions were positive in all the experiments.
Immunohistochemistry staining was processed as previously described (II) and visualized by the use of diaminobenzidine staining. Counterstaining was carried out with Harris hematoxylin (Sigma). Ten sections were analyzed for each animal, and the 10 images were acquired from a randomly selected location in each slide. Digital photos were analyzed with Image-Pro Plus by an observer blinded to the treatment groups.
Quantitative Real-time Polymerase Chain Reaction (qRT-PCR)
The total RNA was extracted from inferior lobs of right lungs using Trizol (Invitrogen, USA) and quantified using a spectrophotometer at 260 nm. Then, total RNA (I ug) was reverse-transcribed with an ImProm-II Reverse Transcription System kit (Promega, USA). The PCR assays were completed using ABI PRISM 7500 Sequence Detection System (Applied Biosystems, USA) under the following conditions: 30 seconds at 95°C, followed by 40 cycles of 5 s at 95°C, 30 s at 55°C, and 34 s at noc. Glyceraldehyde 
3-phosphate dehydrogenase [GAPDH]
was used as an internal standard.
The primers (sense and antisense) for each gene were synthesized as follows: GAPDH, 5'-GCATGGCCTTCCGTGTTC-3' and 5'-GATGTCATCATACTTGGCAGGTTT-3'; TGF-~I, 5' -TGGAAGTGGATCCACGCGCCCAAGG-3' and 5'-GCAGGAGCGCAC GATCATGTTGGAC-3'. All the data were analyzed using a comparative cycle threshold (Ct) method and the equation 2-~Ct (~Ct=Ct (TGF_~I)-Ct (GAPDH) was used to calculate the relative expression of TGF-~1. All experiments were carried out in triplicate.
Western blot analysis
Lung tissues were homogenized in the lysis buffer containing protease inhibitors and protein concentrations were determined using the Bradford reagent (Bio-Rad, USA). Equal amounts of total protein were separated on 12% SDS PAGE gels at 80 V for 80 min and subsequently transferred to PVDF membranes by the wet transfer method (250 rnA, 90 min). After blocking with 5% BSA at 4°C overnight, the membranes were incubated with an anti-IL-13 (sc-101407, Santa Cruz, USA) antibody, anti-TGF-~I (sc-146, Santa Cruz, USA) antibody (dilution I :500) at room temperature for2 h.After being washed with TBST, the membranes were incubated with peroxidaseconjugated secondary antibodies (dilution I: 1500) at room temperature for I h. The membranes were reb lotted with an anti-B-actin antibody (Zhongshan, China) to verify equal loading of protein in each lane. Then proteins were detected by chemiluminescence reagent (GE Healthcare). Expression levels of the proteins were compared with the control based on the relative intensities of the bands. Band density was quantified using the software program Bio-Rad Quantity One v4.62.
Statistical analysis
The statistical analyses were performed with SPSS statistics 11.5. All values were expressed as mean ± S.E.M. Statistical comparisons were made with one-way analysis of variance (ANOVA). P values<0.05 were considered statistically significant.
RESULTS
Low-dose azithromycin arrested ovalbumindependent airway inflammation
To determine whether low-dose azithromycin could confer anti-inflammatory properties in allergic inflammation, we sensitized and challenged rats with ovalbumin as previously described. We first set out to evaluate the suppression of inflammatory cells by AZM in OVA-challenged rats; we counted the number of cells that were recruited to the BALF. Differential leukocyte counts showed that compared with the control group, repetitive OVA challenge in saline-treated rats induced a significant increase in the number of neutrophils, lymphocytes and eosinophils in BALF (P<O.05).AZM therapy in OVAchallenged rats significantly reduced the number of lymphocytes, eosinophils and neutrophils in BAL fluid in comparison with the OVA group (P<O.05) ( Fig. 2A) . Moreover, the effect of AZM on OVAinduced airway inflammation was also illustrated by histological examination. OVA-challenged rats Effect ofazithromycin on differential cell counts in BALF and serum IgE level. A) Rats were processed as described in Fig. I, and displayed severe increase in inflammation score compared to saline-challenged rats (P<O.05) (Fig.  4C ). Treatment with AZM significantly lessened the inflammation score compared to OVA-challenged rats (P<O.05) (Fig. 4C) . A similar effect was found in the dexamethasone group.
Effects of low-dose azithromycin on serum 19E level and the levels of cytokines in BALF and 1L-J3 expression in lung
We observed a boosted level of total IgE in the serum of rats exposed to OVA as compared to the control group rats. Intriguingly, this rise was just declined significantly (P<O.05)in the rats treated with DXM but not AZM (Fig. 2B ). To determine whether low-dose AZM influenced cytokine secretion in BALF, the levels of IL-2, IL-4, IL-5, IL-13 and TNF-a in BALF were also measured using ELISA 24 h after the final OVA challenge. OVA challenge triggered a significant increase in all cytokine levels in BALF (Fig. 3A, B ) compared with those observed in the control group. DXM almost restored all the cytokine levels to normal (P<O.05). Administration ofAZM also resulted in a significant reduction of IL-2, IL-4, IL-5, IL-13 and TNF-a levels in BALF (Fig.  3A, B ) in comparison to saline-treated rats (P<O.05). Moreover, the ratio of IL-2/IL-4 and TNF-a/IL-4 were notably restored by low-dose azithromycin administration (P<O.05) (Fig. 3C, D) .
IL-13 is a key cytok ine in airway inflammation and remodeling, therefore we measured its protein expression in lung by Western blotting. In agreement with the ELISA results, low-dose AZM apparently inhibited the increase of IL-13 expression (P<O.05). There was no significant difference in IL-13 expressions among rats treated with low-do se azithromycin and dexametha sone (P>O.05) (Fig. 7C,  E) .
Effects of low-dose azithromycin on OVA-induced airway remodeling
The effect of low-dose azithromycin on OVA-induced airway remodeling wa s illustrated by histological examination. OVA-challenged rats displayed severe increase in thickness of the peribronchial smooth muscl e layer ( Fig. 48 ) and goblet cell hyperplasia (mucus production) ( Fig.  5 ) compared to saline-challenged rats (P<O.05). The percentage of PAS-po sitive airway epith elial cells increased markedly compared with salinechallenged rats (Fig. 58) . In contrast, treatment with AZM significantly reduced all the thickness of the peribronchial smooth muscle layer (Fig. 48) and increase in the percentage of PAS-positive airway epithelial cells induced by OVA challenge (Fig. 58 effect was found in the OXM group. Airway fibrosis was also studied by the staining of the tissue with Masson trichrome, and evaluated by the score system. The increase in airway fibrosis by OVA challenge was significantly inhibited by treatment with OXM and AZM (Fig. 6 ).
Effects of low-dose azithromycin on the levels of ET-l in BALF
To examine whether the inhibitory effects of low-dose azithromycin was related to a reduction in OVA-specific ET-l production, ET-I in BALF collected from each group of rats were measured. Compared with control group, repetitive OVA challenge with saline-treated rats markedly increased the levels ofET-l in BALF (P<O.05). Treatment with azithromycin reduced the level of ET-l in BALF dramatically compared to rats immunized with OVAl alum alone (Fig. 3B) . A similar effect was found in the OXM group.
Effects of low-dose azithromycin on the expression ofTGF-fJl
TGF-p is a profibrogenic growth factor whose expression is increased in asthma. To test the hypothesis that these effects were coupled to a decreased TGF-pi level, qRT-PCR, immunohistochemistry and Western blotting analysis for mRNA and protein expressions of TGf'-Bl were performed, respectively. It was found that low-dose azithromycin notably decreased TGF -P I protein ( Fig. 7B-0 ) expression level from repetitive OVA challenge rats (P<O.05). This decrease in TGF-p I protein was also observed on the mRNA level following azithromycin treatment (Fig. 7A) . A similar effect was found in dexamethasone group. There was no significant difference in TG F-P I mRNA expressions among rats treated with lowdose azithromycin and dexamethasone (P>O.05), but low-dose azithromycin was obviously better than the effect of dexamethasone on TG F-P I protein level (P<0.05) ( Fig. 7C-O) .
DISCUSSION
Asthma is one of the most common chronic inflammatory diseases. Numerous studies have demonstrated a beneficial effect of macrolides in the treatment of allergic asthma (7, 8, 12) . Low-dose macrolides also showed anti-inflammatory effect (8) and was easily acceptable to patients. However, little is known about the effect of azithromycin on the development of the airway remodeling that is associated with OVA induced asthma. Therefore, we designed this experiment to systemically evaluate the effects of low-dose azithromycin on airway remodeling in allergic asthma rat. In this study, we first demonstrated that low-dose azithromycin (25 mg/kg in rat) relative to 50 mg/kg in mice in the Beigelman study, presents anti-remodeling properties in a rat model of allergic airway inflammation. Importantly, the drug modulated many of the key allergen-associated inflammatory responses including accumulation of neutrophils, lymphocytes and eosinophils, secretion of ET-l, IL-2, IL-4, IL-13 and TNF-a, and mucus cell hyperplasia and thickening of the peribronchial smooth muscle layer coupled to an increased TGF-p 1 level.
Although Brown-Norway rat is the best choice, as they are inbred rats and are genetically predisposed to Th2 type of response, SO rat was able to respond in an allergic way to the OVA antigen (13) and was also used to induce allergic airway inflammation in experimental research (14) . Consistent with the findings derived from previous experimental models (13) , in our experiments, we successfully chose SO rats to establish an allergic airway inflammation and remodeling model. Histological analysis of OVA rat showed largely infiltration of eosinophils in the airway, thickened the basement membranes, goblet cell hyperplasia and airway fibrosis. Moreover, TGF-pl mRNA expression and protein production were significantly increased in this model. Importantly, our present data show that low-dose azithromycin treatment resulted in dramatically reduced accumulation of inflammatory cells in airway lumen (number in BALF ) and the most profound effect was noted on the attenuation of peribronchial eosinophils. We think that the suppression ofperibronchial eosinophilia by low-do se azithrom ycin could be expla ined by the inhibition of the differentiation and migration of eosinophils. Interestingly, the key findings from this study are that system ically admin istered low-dose azithromycin attenuated the thickness of the peribronchial smooth muscle layer, goblet cell hyperplasia and inhibited the airway fibrosis.
Th2 cytokines, such as IL-4 and IL-1 3, are regarded as regulating the recruitment and activation of inflammatory cells and play a vital role in airway remodeling (15) , especially goblet cell hyperpl asia in the lung (16-1 8) . In contrast, Th 1 cells have also been regarded to inhibit bronchial asthma by production of IL-2 and TNF-a ( 19-2 1). Therefore, imbalance of Th I/Th2 cytok ines plays a cruc ial part in the development of airway remodeling (22) . In addition, endothelins (ETs) are the other potent proinflammatory mediators (23) . Endothelin-I (ET-I) is the major subtype of ETs expressed in the airway epithelial and endothelial cells (24) . Several reports have demonstrated that ET-l plays an important role in the development of airway remodeling (25, 26) in asthma (27) . Our data show that all these inflammatory mediators in BALF were significantly decreased with low-dose azithromycin administration. Importantly, low-dose azithromycin markedly restored the ratio ofITransforming growth factor PI, which is expressed by eosinophils (28), is known as a potent fibrotic factor responsible for the synthesis of extracellular matrix. Furthermore, TGF-p I is an important cytokine correlated with the depth of subepithelial fibrosis (29) and collagen deposition (30) in airway remodeling (31) . Indeed, our data indicate that pretreatment with AZM led to a significant decrease in the number of airway eosinophils and TGF-pI levels in rat.
In conclusion, these data imply that low-dose azithromycin significantly reversed established airway remodeling, including peribronchial collagen deposition and goblet cell hyperplasia by reducing both the production of TGF-p I and Th 1-and Th2type cytokine levels in BALF in OVA-induced rat. These results provide further evidence that oral administration of low-dose azithromycin is suitable for the treatment of allergic airway diseases.
